30-day average of 20 articles ยท scale โ100 to +100
Across 20 scored articles from Oct 17 to Nov 15, 2026 (UTC),
the average sentiment of AbbVie news is Bullish (+51)
on a scale from โ100 to +100.
That is about the same as the previous 30 days (+53).
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion.
Bullish +62
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
AI-generated analysis
Key insights
๐ AbbVie shares surged over 23% year-to-date, outperforming the S&P 500's roughly 13% gain as investors assess its transition strategy.
๐ Skyrizi and Rinvoq drove immunology revenue to $8.79 billion (up 15.1%), with Skyrizi up 24.4% and Rinvoq up 24.5%, offsetting a 35.9% decline in Humira.
๐ง The neuroscience portfolio delivered strong growth, increasing revenue by 20.3% to $3.23 billion in the second quarter.
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion to bolster its immunology pipeline with late-stage candidate zumilokibart.
๐ฐ The company reported total second-quarter revenue of $16.99 billion (up 10.2%) and adjusted diluted EPS rose 22.9% on a reported basis.
โ ๏ธ Management expects the Apogee acquisition to have a $0.14 per share dilutive impact on 2026 adjusted EPS, alongside an unfavorable $0.58-per-share impact from acquired IPR&D expenses.
๐ AbbVie's forward P/E is approximately 16.4x, significantly lower than its trailing P/E of 74.88x due to non-recurring acquisition-related items affecting reported earnings.
๐ฎ The company expects 2026 adjusted diluted EPS between $13.87 and $14.07, following a revision to its July outlook.
๐ Humira revenue fell 35.9% to $756 million in the second quarter as AbbVie continues its portfolio transition away from the aging blockbuster.
๐ The Apogee acquisition is expected to close in the third quarter of 2026, adding clinical-stage immunology assets to the pipeline.
๐ Bullish signals
๐AbbVie shares surged over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain.
๐Skyrizi and Rinvoq generated combined immunology revenue of $8.79 billion (up 15.1%), with individual growth rates of 24.4% and 24.5% respectively, effectively offsetting the decline in Humira.
๐ง The neuroscience portfolio demonstrated robust expansion with revenue increasing 20.3% to $3.23 billion in the second quarter.
๐ฐTotal company revenue increased 10.2% on a reported basis to $16.99 billion in the second quarter, while adjusted diluted EPS rose 22.9%.
๐ Risk factors
๐Humira revenue fell 35.9% to $756 million in the second quarter as the company continues its transition away from the aging blockbuster.
โ ๏ธThe acquisition of Apogee Therapeutics for approximately $10.9 billion will have a dilutive impact on 2026 adjusted EPS, including an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the deal itself.
๐AbbVie's trailing P/E ratio is nearly 75x (74.88x), significantly higher than its forward P/E of 16.4x, indicating that reported earnings are currently depressed by significant acquisition-related and other specified items.
Article
AbbVie (NYSE: ABBV) has delivered strong returns in the first half of 2026, with shares surging over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain. The company is currently trading at a forward P/E of approximately 16.4x, which analysts view as reasonable given its growth trajectory, though this contrasts sharply with its trailing P/E of nearly 75x due to significant acquisition-related and other specified items affecting reported earnings.
The core investment thesis for AbbVie centers on its ability to successfully transition away from the declining blockbuster Humira, which saw revenue fall 35.9% in the second quarter to $756 million. This decline has been effectively offset by robust growth in its newer immunology franchises: Skyrizi generated $5.505 billion (up 24.4%) and Rinvoq generated $2.53 billion (up 24.5%), bringing total global net revenue from the immunology portfolio to $8.79 billion, a 15.1% increase.
Beyond immunology, AbbVie's neuroscience portfolio showed particular strength with revenue increasing 20.3% to $3.23 billion in the second quarter. The company is also executing a major strategic expansion by acquiring Apogee Therapeutics for approximately $10.9 billion to add late-stage clinical assets like zumilokibart, expected to close in the third quarter of 2026. However, this acquisition and ongoing pipeline investment will have a dilutive impact on adjusted EPS, with management expecting an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the Apogee deal itself.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
AbbVie (ABBV) has experienced significant share price appreciation over the past five years, returning 211.2% to investors. The article analyzes whether this rally is justified by examining the company's ability to generate future cash flows, specifically utilizing a Discounted Cash Flow (DCF) model anchored in trailing twelve-month free cash flow of approximately $18.3 billion.
The analysis suggests that AbbVie's current share price of $283.40 may be undervalued by roughly 44% relative to its intrinsic value derived from projected cash flows extending into the early 2030s. These projections assume a steady ramp in annual free cash flow, which is critical for the business as it navigates known patent pressures on older drugs like Humira and Imbruvica starting in the early 2030s.
Recent positive developments, including Phase 3 trial results for cancer therapies (specifically EPCORE DLBCL-2) and new approvals in Parkinson's disease, are expected to bolster future cash inflows. While the DCF model indicates a substantial gap between current market price and estimated intrinsic value, community narratives on Simply Wall St suggest AbbVie might be roughly fairly valued depending on successful execution of its pipeline to replace declining revenue streams.
๐ AbbVie delivered 211.2% share price return over past five years.
๐ฐ Trailing twelve-month free cash flow reached approximately $18.3 billion.
๐ DCF model suggests intrinsic value is 44% higher than current price.
๐ฌ Positive oncology and Parkinson's trial results expected to boost future cash flows.
โ ๏ธ Patent expirations on Humira and Imbruvica create early 2030s pressure.
๐ AbbVie has delivered a 211.2% share price return over the past five years, raising questions about whether current gains are supported by sustainable cash generation.
๐ฐ The company reported trailing twelve-month free cash flow of approximately $18.3 billion, serving as the anchor for intrinsic value calculations.
๐ A Discounted Cash Flow (DCF) model estimates AbbVie's intrinsic value is substantially higher than the current share price of $283.40, suggesting a potential 44% undervaluation.
๐ฌ Recent positive Phase 3 trial results for oncology therapies and new Parkinson's disease approvals are expected to contribute positively to future free cash flows.
โ ๏ธ The business faces known patent expiration pressures on key products like Humira and Imbruvica in the early 2030s, necessitating successful pipeline execution.
๐ Community narratives indicate a divergence between DCF-based bullishness and fundamental valuations that suggest AbbVie might be roughly fairly valued.
New cancer/Parkinson's approvals will boost future cash flows.
DCF model shows stock undervalued by 44%.
Risk Factors
Patent expirations for Humira/Imbruvica in early 2030s threaten revenue.
Community views stock as fairly valued, limiting upside potential.
Bullish Signals
The company generated trailing twelve-month free cash flow of approximately $18.3 billion, indicating strong underlying cash generation capabilities.
Recent positive Phase 3 trial results for cancer therapies (EPCORE DLBCL-2) and new Parkinson's disease approvals are expected to add oncology contributors to future free cash flows.
A Discounted Cash Flow (DCF) model estimates the stock is undervalued by roughly 44% relative to its projected intrinsic value based on growing cash flow assumptions.
Risk Factors
The company faces known patent expiration pressures on older drugs like Humira and Imbruvica in the early 2030s, which could impact future revenue streams if not replaced by new products.
Community narratives suggest AbbVie might be roughly fairly valued rather than undervalued, implying that current positive trial results may not fully justify a significant price premium.
AbbVie (ABBV) shares surged 3.32% on October 14, 2026, trading near a 52-week high of $285.40 with record-breaking volume and $1.59 billion in turnover. The rally was driven by a confluence of strong fundamental performance and unusual bullish options activity, signaling significant institutional and retail interest in the pharmaceutical giant.
The company reported robust third-quarter results that exceeded analyst expectations, posting EPS of $3.65 versus a consensus of $3.61 and revenue of $16.99 billion, which represented a 10.2% year-over-year increase. Management provided optimistic guidance for the fourth quarter, projecting EPS between $3.84 and $3.88, reinforcing confidence in the company's operational resilience and profitability amidst a challenging macroeconomic environment.
Analyst sentiment remains predominantly positive, with major firms like Wolfe Research and Barclays upgrading their outlooks to 'Outperform' or 'Overweight' with price targets set at $300. Institutional investors have further validated this bullish case, adding billions in new stakes, while the company's status as a dividend aristocrat continues to attract income-focused capital despite concerns over its high valuation metrics.
๐ Shares surged 3.32% on record $1.59B turnover and strong institutional buying.
๐ฐ Q3 EPS beat at $3.65; revenue hit $16.99B, up 10.2% year-over-year.
๐ฎ Management projects Q4 EPS between $3.84 and $3.88.
๐ Analysts upgraded targets to $300 citing strong fundamentals.
๐ฆ Legal & General Group added a new $2.9 billion stake.
๐ AbbVie shares surged 3.32% to near $285.40 on record $1.59 billion turnover and strong institutional buying.
๐ฐ Q3 EPS beat estimates at $3.65 vs $3.61, while revenue reached $16.99 billion, a 10.2% year-over-year increase.
๐ฎ Management provided optimistic Q4 guidance with projected EPS between $3.84 and $3.88.
๐ Analysts upgraded targets to $300, citing strong fundamentals despite the stock trading above consensus price targets.
๐ฆ Major institutional investors added significant stakes, including Legal & General Group Plc establishing a new $2.9 billion position.
AbbVie Inc. reported second-quarter 2026 revenue of USD 16.99 billion, representing a 10.20 percent year-over-year increase. The company also delivered adjusted earnings per share of USD 3.65, which beat the market consensus estimate of USD 3.61 by four cents. This positive performance provides a solid baseline as investors await the upcoming third-quarter results.
Market analysts and data providers project AbbVie's third-quarter revenue to reach USD 17.34 billion with adjusted earnings per share expected at USD 3.80. The company is scheduled to release these Q3 figures on October 30, 2026, before the market opens, followed by a conference call at 9:00 a.m. ET. These upcoming metrics will serve as critical tests against the higher revenue bar set for the quarter.
Equity research firm Morgan Stanley recently raised its price target for AbbVie from USD 296.00 to USD 310.00 while maintaining an overweight rating, signaling continued confidence in the stock's trajectory. Additionally, AbbVie has an ex-dividend date of October 15, 2026, offering a quarterly dividend of USD 1.73 per share, providing near-term value to shareholders alongside the anticipated earnings release.
Currently trading at EUR 245.55, AbbVie stock sits approximately 3.06 percent below its 52-week high of EUR 253.30. With a market capitalization of EUR 434.6 billion, the pharmaceutical giant operates within the Healthcare sector and is positioned to deliver results that could influence its valuation relative to recent highs.
๐ AbbVie Q2 2026 revenue rose 10.2% to USD 16.99 billion.
๐ฐ Adjusted EPS beat consensus by four cents at USD 3.65.
๐ฏ Morgan Stanley raised price target to USD 310 with overweight rating.
๐ต Ex-dividend date set for October 15, 2026, at USD 1.73/share.
๐ Stock trades EUR 245.55, down 3.06% from 52-week high.
๐ AbbVie reported second-quarter 2026 revenue of USD 16.99 billion, up 10.20 percent year over year.
๐ฐ The company beat analyst consensus for adjusted earnings per share by four cents at USD 3.65.
๐ Third-quarter results are scheduled for release on October 30, 2026, before the market opens.
๐ฏ Morgan Stanley raised its price target to USD 310.00 and maintained an overweight rating.
๐ต AbbVie has an ex-dividend date of October 15, 2026, with a quarterly dividend of USD 1.73 per share.
๐ Stock is currently trading at EUR 245.55, sitting 3.06 percent below its 52-week high.
๐ข The company has a market capitalization of EUR 434.6 billion as of October 14, 2026.
Bullish Signals
Revenue grew 10.20% YoY to USD 16.99 billion in Q2 2026.
EPS beat consensus by four cents at USD 3.65.
Morgan Stanley raised price target to USD 310.00 with overweight rating.
Quarterly dividend set at USD 1.73 per share.
Bullish Signals
AbbVie reported second-quarter 2026 revenue of USD 16.99 billion, marking a robust 10.20 percent year-over-year increase.
The company beat analyst consensus for adjusted earnings per share by four cents, delivering USD 3.65 versus the expected USD 3.61.
Morgan Stanley raised its price target from USD 296.00 to USD 310.00 while maintaining an overweight rating on the stock.
AbbVie is set to pay a quarterly dividend of USD 1.73 per share with an ex-dividend date of October 15, 2026.
AbbVie (ABBV) has recently generated significant market attention following a series of positive clinical data readouts and regulatory milestones across its immunology, oncology, and metabolic franchises. Key developments include Phase 3 results for SKYRIZI and RINVOQ in Crohn's disease, FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer, early obesity data for ABBV-295, and Phase 2 results for zumilokibart in atopic dermatitis.
The stock has rallied to US$281.12, reflecting a 9.33% return over the past month and a 22.59% year-to-date gain. Total shareholder return stands at 25.85% over one year, with performance more than doubling over three and five-year periods. This momentum suggests investors are reassessing the company's growth potential and pipeline risk following these updates.
Valuation perspectives on AbbVie remain divergent. While analyst consensus pegs fair value near the current price of US$281.12, suggesting a slight overvaluation, an SWS DCF model estimates a fair value of US$497.77, implying the stock trades approximately 43.5% below that intrinsic value. Management reports that Humira erosion of roughly US$18 billion has been offset by US$28 billion in growth from other platforms, with 2026 guidance projected to be nearly US$10 billion above pre-Humira peaks.
๐ AbbVie received FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer.
๐ Early obesity data for ABBV-295 and Phase 2 zumilokibart results boost pipeline momentum.
๐ Stock gained 9.33% in one month, reaching US$281.12 with a 25.85% one-year total return.
โ ๏ธ Risks include drug price pressure and faster-than-expected competition for SKYRIZI and RINVOQ.
๐ AbbVie recently delivered Phase 3 readouts for SKYRIZI and RINVOQ in Crohn's disease alongside new FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer.
๐ Early obesity data for ABBV-295 and Phase 2 results for zumilokibart in atopic dermatitis have added to the pipeline momentum ahead of the next earnings update.
๐ Share price climbed to US$281.12, delivering a 9.33% one-month return and a 22.59% year-to-date gain as investors reassess growth potential.
๐ฐ Total shareholder return sits at 25.85% over one year, with performance more than doubling over three and five-year periods indicating sustained investor confidence.
๐ Management reports that Humira erosion of approximately US$18 billion has been fully offset by roughly US$28 billion of growth from newer platforms.
๐ 2026 guidance is projected to be almost US$10 billion above the pre-Humira peak, reinforcing the case for revenue diversification and long-term stability.
โ๏ธ Analyst consensus fair value is pegged at US$278.61, which is nearly level with the latest close of US$281.12, leaving a narrow gap for new buyers.
๐ The SWS DCF model estimates a fair value of US$497.77, framing the current price of US$281.12 as trading about 43.5% below estimated intrinsic value.
โ ๏ธ Key risks to the bullish narrative include potential tightening drug price pressure and faster-than-expected competition for SKYRIZI and RINVOQ.
Bullish Signals
Phase 3 readouts for SKYRIZI and RINVOQ reinforced core immunology strength.
FDA Breakthrough Therapy Designations secured for Temab-A in cancer.
Early obesity data for ABBV-295 shows continued metabolic innovation.
Share price climbed to US$281.12 with 9.33% one-month return.
Total shareholder return reached 25.85% over one year.
Risk Factors
Drug price pressure threatens revenue growth.
Competition erodes SKYRIZI/RINVOQ market share.
Bullish Signals
AbbVie delivered positive Phase 3 readouts for SKYRIZI and RINVOQ in Crohn's disease, reinforcing the strength of its core immunology franchises.
The company secured new FDA Breakthrough Therapy Designations for Temab-A in colorectal and lung cancer, signaling regulatory confidence in its oncology pipeline.
Early obesity data for ABBV-295 and Phase 2 results for zumilokibart in atopic dermatitis demonstrate continued innovation across metabolic and skin disease segments.
Share price climbed to US$281.12 with a 9.33% one-month return and 22.59% year-to-date gain, reflecting strong market momentum.
Total shareholder return reached 25.85% over one year, with performance more than doubling over three and five-year periods.
Management reports that Humira erosion of approximately US$18 billion has been offset by roughly US$28 billion of growth from other platforms.
2026 guidance is projected to be almost US$10 billion above the pre-Humira peak, validating the success of post-Humira diversification strategy.
Risk Factors
Key risks to the bullish narrative include potential tightening drug price pressure that could impact revenue growth from blockbuster franchises.
SKYRIZI and RINVOQ face faster-than-expected competition in the immunology market, which could erode market share and pricing power.
AbbVie Inc. announced the presentation of 22 abstracts focused on inflammatory bowel disease at the American College of Gastroenterology (ACG) meeting held in October 2026. The company highlighted significant clinical data for its key products, SKYRIZI and RINVOQ, demonstrating strong efficacy in treating fistulizing disease and isolated ileal disease with high rates of steroid-free remission.
Financially, AbbVie reported robust second-quarter 2026 results with revenue reaching USD 16.99 billion, representing a 10.20 percent year-over-year increase. Adjusted earnings per share stood at USD 3.65, which beat the consensus estimate of USD 3.61. Following these results and the positive clinical data presentation, the stock price appreciated to EUR 247.55.
The company recently completed its acquisition of Apogee Therapeutics for USD 10.9 billion, with initial R&D expenses totaling USD 216 million recorded in October. Analysts remain bullish on the stock, with Guggenheim reaffirming a Buy rating and setting a price target of USD 288.00, reflecting confidence in AbbVie's pipeline and execution capabilities.
Looking ahead, investors will await AbbVie's third-quarter 2026 earnings report scheduled for October 30, 2026. The company continues to leverage its immunology portfolio, presenting both controlled trial evidence and real-world treatment outcomes to reinforce its market position in gastroenterology.
๐ AbbVie Q2 2026 revenue hit USD 16.99 billion, up 10.20%.
AbbVie (ABBV) investors who purchased shares during periods of market pessimism and uncertainty have historically outperformed those who bought on headlines of positive drug approvals. Data indicates that buying during the 2019 Allergan selloff yielded a 449% return, significantly surpassing the 357% return for investors who entered the market following Skyrizi's approval in April 2019. This pattern suggests that good news often coincides with higher entry prices, potentially trapping buyers who fail to recognize the valuation implications of immediate positive catalysts.
The company continues to execute its strategy of replacing blockbuster revenue with new immunology and oncology assets. Second-quarter 2026 sales for Skyrizi reached $5.51 billion, a 24.4% increase, while Rinvoq sales grew 24.5% to $2.53 billion. Neuroscience revenue also expanded by 20.3% to $3.23 billion in the same period, demonstrating diversification beyond its primary reliance on Humira as that product faces a steep decline following biosimilar competition.
AbbVie has successfully navigated the transition from its spinoff in 2013 and the subsequent Allergan acquisition, which closed in May 2020. The company is now focused on managing the 'revenue cliff' associated with Humira's expiration while leveraging new products like Imbruvica and recent ImmunoGen acquisitions to drive growth. Management expects an injectable form of Skyrizi for Crohn's disease to boost sales starting in early 2027, alongside adjusted EPS guidance for 2026 ranging between $13.76 and $13.96.
๐ AbbVie delivered 537% total return over ten years, beating S&P 500's 260%.
๐ Skyrizi sales hit $5.51B in Q2 2026 with 24.4% year-over-year growth.
โ ๏ธ Humira sales fell 35.9% as first U.S. biosimilar entered the market.
๐ง Neuroscience revenue expanded 20.3% to $3.23B following Allergan acquisition.
๐ Investors who bought AbbVie during the 2019 Allergan selloff achieved a 449% return, outperforming those who bought on Skyrizi's approval which returned 357%.
๐ AbbVie has delivered a 537% total return over ten years, significantly beating the S&P 500 index's 260% gain across every measured time window.
๐ Second-quarter 2026 sales for Skyrizi reached $5.51 billion, representing a 24.4% year-over-year increase driven by strong immunology demand.
๐ฌ Rinvoq sales grew 24.5% to $2.53 billion in the second quarter of 2026, validating the company's strategy for replacing Humira revenue.
๐ง Neuroscience revenue expanded 20.3% to $3.23 billion in Q2 2026 following the completion of the Allergan acquisition.
โ ๏ธ Humira sales fell 35.9% to $756 million in Q2 2026 as the first U.S. biosimilar entered the market, marking the arrival of the revenue cliff.
๐ฏ The ImmunoGen acquisition completed in February 2024 added cancer drugs to the portfolio, though Imbruvica sales declined 29.4% in Q2 2026.
๐ An injectable form of Skyrizi for Crohn's disease is expected to boost sales beginning in early 2027.
๐ AbbVie provided adjusted EPS guidance for 2026 between $13.76 and $13.96, reflecting management's outlook on earnings growth.
๐ Historical data suggests that buying on headline-grabbing drug approvals often results in lower returns compared to buying during periods of fear.
Bullish Signals
Investors gained 449% buying during 2019 Allergan selloff.
Delivered 537% total return over ten years.
Skyrizi sales reached $5.51B in Q2 2026, up 24.4%.
Rinvoq sales grew 24.5% to $2.53B in Q2 2026.
Neuroscience revenue grew 20.3% to $3.23B in Q2 2026.
Risk Factors
Humira sales fell 35.9% to $756M in Q2 2026 due to biosimilar entry.
Imbruvica sales declined 29.4% in Q2 2026 after ImmunoGen acquisition.
Bullish Signals
AbbVie investors who bought during the 2019 Allergan selloff earned a 449% return, significantly outperforming those who bought on Skyrizi's approval.
The company has delivered a 537% total return over ten years, beating the S&P 500 index by more than double across every measured time window.
Second-quarter 2026 sales for Skyrizi reached $5.51 billion, up 24.4%, demonstrating strong growth in its key immunology franchise.
Rinvoq sales grew 24.5% to $2.53 billion in Q2 2026, confirming the success of its second major Humira replacement strategy.
Neuroscience revenue grew 20.3% to $3.23 billion in the second quarter of 2026 following the Allergan acquisition closure.
Management expects an injectable form of Skyrizi for Crohn's disease to boost sales beginning in early 2027, providing a new growth vector.
Risk Factors
Humira sales fell 35.9% to $756 million in the second quarter of 2026 as the first U.S. biosimilar reached the market.
Imbruvica, AbbVie's older cancer drug, declined 29.4% in the second quarter of 2026 following the ImmunoGen acquisition.
AbbVie (NYSE: ABBV) reported strong financial performance in the latest quarter, with total revenue climbing 10.2% to $16.99 billion despite a significant 35.9% decline in its blockbuster drug Humira sales, which fell to $756 million. The company successfully offset this loss with robust growth from its successor immunology drugs, Skyrizi and Rinvoq, which collectively drove immunology segment revenue up 15.1% to $8.786 billion.
Beyond immunology, AbbVie demonstrated diverse growth across other therapeutic areas, including a 20.3% increase in neuroscience sales to $3.228 billion and modest gains in oncology and aesthetics segments. Adjusted earnings per share rose 22.9% to $3.65, supported by strong operational performance, though the company incurred one-time acquired research expenses of $0.17 per share. Management provided full-year adjusted EPS guidance ranging between $13.87 and $14.07.
The company recently completed its acquisition of Apogee Therapeutics for $10.9 billion to bolster its future immunology pipeline, specifically targeting the lead candidate zumilokibart. While this deal is expected to reduce adjusted EPS by approximately $0.46 in 2027 before becoming accretive in 2032, it represents a strategic long-term investment. Analysts note that while the stock trades at a forward P/E of 18.97, slightly above its five-year average, the valuation reflects investor confidence in the company's ability to sustain growth as Humira's patent exclusivity wanes.
Investors are closely monitoring the sustainability of Skyrizi and Rinvoq growth rates against the looming patent cliff for these drugs within the next decade. Hedge fund ownership has increased slightly, with short interest remaining low at 1.23%, indicating continued support from institutional investors. The article concludes that AbbVie appears fairly priced for long-term investors comfortable with pipeline dependence, though a slowdown in successor drug growth or higher acquisition costs could alter this outlook.
๐ Revenue rose 10.2% to $16.99B as Skyrizi and Rinvoq offset Humira decline.
๐ Immunology segment grew 15.1% driven by strong sales of Skyrizi and Rinvoq.
๐ง Neuroscience sales surged 20.3%, signaling a second growth leg for the company.
๐ฐ Adjusted EPS rose 22.9% to $3.65 despite one-time research expenses.
AbbVie Inc. has lowered its third-quarter 2026 adjusted earnings per share (EPS) guidance to a range of USD 3.730-3.770, which falls below the market consensus estimate of USD 3.850. The company attributes this downward revision primarily to acquired in-process research and development costs and milestone expenses totaling USD 216 million.
Despite the guidance cut, AbbVie reported robust financial performance for the second quarter of 2026, generating revenue of USD 16.99 billion, a 10.2% year-over-year increase. Adjusted EPS for Q2 reached USD 3.65, significantly beating the prior-year figure of USD 2.97, indicating strong underlying operating growth.
Analyst sentiment remains cautiously optimistic despite the guidance adjustment. Major institutions like Bank of America have maintained Buy ratings and raised price targets, with an average analyst target currently standing at USD 278.86. The stock is trading near its 52-week high, suggesting investors are weighing the near-term expense headwinds against long-term growth potential.
AbbVie is scheduled to release its official third-quarter results on October 30, 2026, before the market opens. Market attention will focus on whether the company's revenue growth trajectory can successfully offset the impact of the lower EPS guidance and the specific expense items included in the revision.
AbbVie Inc. reported strong second-quarter financial performance with revenue reaching USD 16.99 billion, representing a 10.2% increase year-over-year. Adjusted diluted earnings per share (EPS) surged by 22.9% to USD 3.65, driven by the successful commercialization of newer medicines like Skyrizi and Rinvoq which are effectively offsetting revenue pressure from legacy products.
The company is currently under direct investor scrutiny regarding its post-Humira growth strategy as it approaches the release of third-quarter 2026 results on October 30. Analysts view this upcoming quarter as a critical checkpoint to evaluate the early commercial outlook for Juvmo and the continued execution capabilities required to manage Humira's patent erosion and competitive landscape.
Market sentiment remains cautiously optimistic with a Moderate Buy consensus from 31 brokerages, including multiple Strong Buy ratings. The average one-year price target of USD 272.66 sits 3.75% above the recent trading price, reflecting confidence in AbbVie's ability to navigate its transition while maintaining robust financial metrics and delivering on strategic growth targets.
๐ Q2 revenue surged 10.2% to USD 16.99 billion.
๐ฐ Adjusted diluted EPS rose 22.9% to USD 3.65.
๐ Skyrizi and Rinvoq offset legacy product revenue pressure.
โ ๏ธ Stock faces pressure from Humira erosion and competition.
๐ฏ Analysts maintain Moderate Buy with USD 272.66 target.
๐ AbbVie reported Q2 revenue of USD 16.99 billion, marking a significant 10.2% year-over-year growth.
๐ฐ Adjusted diluted EPS increased by 22.9% to reach USD 3.65 in the second quarter.
๐ Newer medicines Skyrizi and Rinvoq are successfully offsetting revenue pressure from legacy products.
๐ The company is scheduled to release third-quarter 2026 results before the market opens on October 30.
๐ฏ Analysts maintain a Moderate Buy consensus with an average one-year price target of USD 272.66.
โ ๏ธ Investors are closely monitoring the early commercial outlook for Juvmo as a key growth driver.
๐ The stock faces potential pressure from ongoing Humira erosion and increasing market competition.
๐ต AbbVie's market capitalization stands at USD 464.3 billion as of October 2, 2026.
๐ฅ The company operates in the Healthcare sector specifically within Drug Manufacturers - General.
Bullish Signals
Revenue grew 10.2% YoY to $16.99B in Q2.
Adjusted EPS surged 22.9% to $3.65.
New drugs offset legacy product revenue decline.
Analysts rate Moderate Buy with $272.66 target.
Risk Factors
Humira revenue pressure from waning patent protection.
Competition threatens growth in therapeutic areas.
Investors scrutinize Juvmo's early commercial outlook.
Bullish Signals
AbbVie achieved a robust 10.2% year-over-year revenue growth to USD 16.99 billion in Q2, demonstrating strong top-line expansion.
Adjusted diluted EPS surged by 22.9% to USD 3.65, highlighting significant profitability improvements and operational efficiency.
The company successfully leverages newer medicines like Skyrizi and Rinvoq to offset declining revenue from legacy products.
Analysts maintain a Moderate Buy consensus with an average price target of USD 272.66, indicating confidence in future performance.
Risk Factors
The company faces ongoing revenue pressure due to the erosion of its blockbuster drug Humira as patent protection wanes.
Increasing competition in the therapeutic areas where AbbVie operates poses a risk to maintaining current growth trajectories.
Investors are scrutinizing the early commercial outlook for Juvmo, which must build sufficient demand to meet expectations.
Company updateEarnings reportAI-generated analysis
AbbVie (ABBV) has successfully navigated the patent cliff of its blockbuster drug Humira, achieving revenue growth of 10.20% in the most recent quarter compared to a sector average that often sees shrinkage. The company generated $64.39 billion in trailing twelve-month revenue and maintains a robust 40.04% operating margin, driven by the rapid expansion of its new therapies Skyrizi and Rinvoq which now cover the revenue gap left by Humira's loss of exclusivity.
Despite its strong operational performance, AbbVie carries significant debt totaling $70.88 billion due to the acquisitions required to secure its replacement drugs, resulting in a levered free cash flow of $16.87 billion. This financial structure impacts its bottom-line net margin, which stands at 9.80%, lower than rival Bristol Myers Squibb (BMY) at 18.87%. Consequently, AbbVie trades at a higher forward multiple of 16.39x compared to BMY's 9.36x, reflecting the market's pricing of its successful transition versus BMY's cheaper valuation.
Analysts and hedge funds view AbbVie as the superior business model for patent transitions, noting that its growth is more sustainable as Skyrizi and Rinvoq are in the early years of their patent protection. However, investors must weigh this operational strength against the high debt load and premium valuation, while BMY offers a cheaper entry point with higher net margins but faces its own upcoming patent erosion risks from Eliquis and Revlimid.
The article compares Eli Lilly (LLY) and AbbVie (ABBV), highlighting that while Lilly commands a premium valuation driven by rapid growth in its obesity pipeline, AbbVie offers a distinct profile characterized by stronger free cash flow generation and a higher dividend yield. As of October 1, 2026, Lilly trades at 13.26 times trailing sales with revenue up 49.6% year-over-year, whereas AbbVie trades at 7.31 times sales with revenue growth of 10.4%.
AbbVie is leveraging its robust cash generation to fund significant pipeline expansion, including the recent $10.9 billion acquisition of Apogee Therapeutics which adds assets zumilokibart and APG273. The company reaffirmed its 2026 adjusted EPS guidance despite expected dilution from the deal, with analysts maintaining Buy ratings and raising price targets based on the potential of these new assets alongside its existing immunology franchise.
Institutional positioning has increased for both companies in the second quarter of 2026, with major hedge funds like Citadel significantly increasing their stakes in AbbVie. The article concludes that the valuation gap between the two reflects their different financial strategies: Lilly's heavy reinvestment in manufacturing and growth versus AbbVie's focus on cash flow sustainability and shareholder returns.
๐ AbbVie trades at 7.31x sales vs. Eli Lilly's 13.26x multiple.
๐ฐ Generated $16.87B free cash flow, $5.8B more than Eli Lilly.
๐ญ Completed $10.9B Apogee acquisition adding zumilokibart and APG273.
๐ BofA raised price target to $282 with Buy rating maintained.
๐ Phase 2 data shows 7.8% to 9.8% weight reduction at Week 12.
๐ As of October 1, 2026, AbbVie trades at a 7.31x trailing sales multiple compared to Eli Lilly's 13.26x, reflecting slower growth but stronger cash generation.
๐ฐ AbbVie generated $16.87 billion in levered free cash flow in the trailing period, which is $5.8 billion more than Eli Lilly despite Lilly's higher revenue.
๐ญ AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics on September 3 to add zumilokibart and APG273 to its pipeline.
๐ Analyst BofA raised its price target for AbbVie to $282 on September 8, maintaining a Buy rating after incorporating the new Apogee assets into estimates.
๐ Phase 2 data for zumilokibart (ABBV-295) showed weight reductions of 7.8% to 9.8% at Week 12, with every-other-week dosing achieving 9.7% reduction.
๐ The Apogee acquisition is expected to dilute AbbVie's adjusted EPS by $0.14 in 2026 and about $0.46 in 2027 before becoming accretive in 2032.
๐ฆ Institutional ownership increased significantly, with Citadel increasing its position by 547% and AQR Capital Management by 127% in the second quarter of 2026.
๐ต AbbVie offers a forward dividend yield of 2.63%, contrasting with Eli Lilly's 0.58% yield, reflecting different capital allocation priorities.
๐ AbbVie carries $70.89 billion in debt with a debt-to-EBITDA ratio of 2.28 times, which is higher than Eli Lilly's 1.31x leverage.
Bullish Signals
Levered free cash flow hit $16.87 billion.
Reaffirmed 2026 EPS guidance of $13.87-$14.07.
Phase 2 zumilokibart data met primary endpoints.
Citadel raised position by 547% in Q2 2026.
BofA raised price target to $282.
Risk Factors
Apogee acquisition dilutes EPS by $0.14 in 2026 and $0.46 in 2027.
Debt load of $70.89B with 2.28x debt-to-EBITDA ratio.
Bullish Signals
AbbVie generated $16.87 billion of levered free cash flow in the trailing period, significantly outpacing Eli Lilly's cash generation despite lower revenue growth.
The company reaffirmed its 2026 adjusted EPS guidance of $13.87 to $14.07 following the Apogee Therapeutics acquisition, demonstrating confidence in future earnings power.
Phase 2 data for zumilokibart met primary endpoints with weight reductions of 7.8% to 9.8% at Week 12, validating the pipeline's potential in the obesity market.
Major institutional investors are increasing exposure, with Citadel raising its position by 547% and AQR Capital Management by 127% in Q2 2026 filings.
Analyst BofA raised its price target to $282 from $276 on September 8, maintaining a Buy rating after adding zumilokibart to their investment thesis.
Risk Factors
The Apogee Therapeutics acquisition is expected to dilute adjusted EPS by $0.14 in 2026 and about $0.46 in 2027, delaying accretion until 2032.
AbbVie carries a higher debt load of $70.89 billion with a debt-to-EBITDA ratio of 2.28 times compared to Eli Lilly's more conservative 1.31x leverage.
AbbVie announced positive Phase 2 clinical trial results for zumilokibart, a monoclonal antibody targeting IL-13, in adults with moderate-to-severe atopic dermatitis. The data indicates that all tested dose regimens successfully met the primary endpoint, demonstrating significant improvements in both skin severity and itch reduction.
Following these encouraging findings, AbbVie plans to advance zumilokibart into Phase 3 clinical trials. This development represents a strategic progression for the company's pipeline in the dermatology space, aiming to validate the efficacy of this new therapeutic candidate before potential regulatory submission.
๐ AbbVie's zumilokibart showed significant improvement in atopic dermatitis patients.
โ All dose regimens met primary endpoints for skin and itch relief.
๐ AbbVie advances zumilokibart into Phase 3 clinical trials based on data.
๐ AbbVie reported positive Phase 2 results for zumilokibart, an IL-13 targeting monoclonal antibody, in patients with moderate-to-severe atopic dermatitis.
โ All dose regimens evaluated in the trial met the primary endpoint, showing significant improvements in skin severity and itch relief.
๐ The company has decided to advance zumilokibart into Phase 3 clinical trials based on the successful Phase 2 data.
Bullish Signals
Phase 2 trial showed significant improvements in skin severity and itch reduction.
Advancing zumilokibart to Phase 3 for moderate-to-severe atopic dermatitis.
Bullish Signals
AbbVie achieved positive results in its Phase 2 trial for zumilokibart, demonstrating significant improvements in skin severity and itch reduction across all dose regimens.
The company is advancing zumilokibart into Phase 3 trials, indicating confidence in the drug's potential to treat moderate-to-severe atopic dermatitis.
AbbVie Inc. (ABBV) traded at EUR 232.75 in after-hours trading on September 29, 2026, representing a slight decline of 0.47% against the prior close of EUR 233.85. The stock movement occurred following market hours and reflects minor volatility relative to the previous session's closing price.
In strategic developments, AbbVie announced a new partnership with Valkai, a life sciences artificial-intelligence platform, aimed at enhancing its clinical development capabilities. This collaboration is designed to deploy purpose-built AI tools across targeted areas of clinical research, with the specific goal of improving operational efficiency and accelerating the generation of critical insights for drug discovery processes.
On the regulatory front, AbbVie received approval from the U.S. Food and Drug Administration (FDA) for JUVMO (tavapadon) to treat adults with Parkinson's disease. The company plans to make this selective D1/D5 receptor agonist available to patients in the United States starting in October 2026, marking a significant expansion into its neurology portfolio.
๐ AbbVie stock closed down 0.47% at EUR 232.75 after-hours on Sept 29, 2026.
๐ค AbbVie partners with Valkai to integrate AI into clinical development workflows.
โก Collaboration deploys purpose-built AI to speed up insights in targeted research areas.
โ FDA approved JUVMO for treating adults with Parkinson's disease.
๐ AbbVie expects U.S. launch of JUVMO in October 2026.
๐ AbbVie stock closed at EUR 232.75 after-hours on September 29, 2026, down 0.47% from the prior close of EUR 233.85.
๐ค The company announced a strategic partnership with Valkai to integrate artificial intelligence into its clinical development workflow.
โก This collaboration aims to deploy purpose-built AI capabilities to improve efficiency and speed up insights in targeted clinical research areas.
โ AbbVie secured FDA approval for JUVMO (tavapadon) for the treatment of adults with Parkinson's disease.
๐ The company expects to launch JUVMO for U.S. patients in October 2026 following regulatory clearance.
Bullish Signals
FDA approved JUVMO for Parkinson's treatment.
Launching JUVMO in US by Oct 2026.
Risk Factors
Stock fell 0.47% to EUR 232.75 in after-hours trading.
Bullish Signals
AbbVie secured FDA approval for JUVMO (tavapadon), a selective D1/D5 receptor agonist, expanding its treatment options for adults with Parkinson's disease.
The company plans to launch the newly approved drug JUVMO in the U.S. market in October 2026, creating new revenue potential in the neurology segment.
Risk Factors
AbbVie stock declined 0.47% in after-hours trading on September 29, 2026, closing at EUR 232.75 versus a prior close of EUR 233.85.
AbbVie (ABBV) announced that the FDA has approved Juvmo, a new once-daily tablet containing tavapadon for treating Parkinson's disease. This approval marks a significant regulatory milestone as Juvmo is the first and only selective D1/D5 receptor agonist approved for this condition, offering a distinct mechanism of action compared to existing dopamine agonists that primarily target D2/D3 receptors.
The drug addresses critical limitations in current Parkinson's therapies by providing an alternative or adjunct treatment to levodopa. Clinical data from the TEMPO trial program indicates that Juvmo can help slow the progression of disease-related complications, such as dyskinesia and motor fluctuations. Specifically, 93% of participants did not require an increase in their levodopa dose after 85 weeks of treatment, compared to a worsening trend in the placebo group.
In terms of efficacy, patients taking Juvmo experienced a 22% to 23% improvement in daily living scores relative to baseline, while the placebo group declined by 12%. For those already on levodopa, the drug increased 'on' time by 1.7 hours versus 0.6 hours for placebo and reduced 'off' time by 1.9 hours versus 0.9 hours. AbbVie projects that Juvmo will be available to patients in the U.S. starting in October 2026.
The safety profile was described as favorable, with side effects mostly being mild to moderate, including nausea, headache, and dizziness. While dyskinesia and hallucinations were noted as common side effects when combined with levodopa, AbbVie's Chief Scientific Officer characterized this approval as the first major dopaminergic breakthrough for Parkinson's in decades, a sentiment echoed by external experts and patient advocacy groups.
๐ FDA approved Juvmo, AbbVie's first selective D1/D5 agonist for Parkinson's disease.
๐ 93% of patients maintained stable levodopa dosing after 85 weeks on Juvmo.
โก TEMPO trials showed 22-23% improvement in daily living scores versus placebo decline.
๐ Drug increased 'on' time by 1.7 hours and reduced 'off' time by 1.9 hours.
๐ AbbVie confirms U.S. availability for Juvmo starting October 2026.
๐ The FDA approved Juvmo (tavapadon), AbbVie's first selective D1/D5 receptor agonist for Parkinson's disease, distinguishing it from existing D2/D3-targeting therapies.
๐ Clinical data shows 93% of patients maintained stable levodopa dosing after 85 weeks on Juvmo, compared to a worsening trend in the placebo group.
โก Patients treated with Juvmo saw a 22-23% improvement in daily living scores versus a 12% decline for the placebo group in the TEMPO trials.
๐ The drug increased 'on' time by 1.7 hours and reduced 'off' time by 1.9 hours compared to placebo in patients already taking levodopa.
๐ AbbVie confirmed that Juvmo will be available to U.S. patients starting in October 2026, providing a new treatment option for motor symptom control.
โ ๏ธ Common side effects include nausea, headache, and dizziness; dyskinesia and hallucinations were observed when combined with levodopa but the overall safety profile was deemed favorable.
Bullish Signals
FDA approved Juvmo, first D1/D5 agonist for Parkinson's.
Bullish Signals
AbbVie secured FDA approval for Juvmo, a novel once-daily tablet that is the first selective D1/D5 receptor agonist approved for Parkinson's disease.
Clinical trials demonstrated that 93% of patients on Juvmo did not need to increase their levodopa dose after 85 weeks, addressing a key limitation of current therapies.
The drug showed statistically significant efficacy with a 22-23% improvement in daily living scores compared to a 12% decline in the placebo group.
Juvmo extended 'on' time by 1.7 hours and reduced 'off' time by 1.9 hours versus placebo, offering substantial benefits for patients on existing levodopa regimens.
AbbVie's Chief Scientific Officer described the approval as a major dopaminergic breakthrough for Parkinson's in decades, validating the strategic value of the asset.
The European Commission has granted approval for AbbVie's new therapy designed to treat active polyarticular juvenile idiopathic arthritis (pJIA) in DMARD-inadequate responders. This regulatory milestone specifically covers patients aged two years and older, marking a significant expansion of the drug's authorized use within the European market.
This approval represents a major strategic win for AbbVie as it solidifies its position in the pediatric rheumatology space with a novel treatment option. The decision validates the efficacy and safety profile of the therapy under European standards, potentially opening new revenue streams and strengthening the company's pipeline of approved biologics and small molecules.
The regulatory clearance is expected to facilitate broader market access across Europe, allowing AbbVie to commercialize the therapy in multiple jurisdictions following this initial approval. This development underscores the company's continued success in developing targeted therapies for rare and complex autoimmune conditions, contributing to its long-term growth strategy.
๐ช๐บ EC approves therapy for active polyarticular juvenile idiopathic arthritis in DMARD-IR patients aged two+.
๐ถ Expands authorized population to include young children as young as two years old.
๐ Validates efficacy and safety of novel treatment for specific pediatric rheumatology subset.
๐ Facilitates commercialization across multiple European jurisdictions, driving future revenue growth.
๐ Reinforces leadership in developing targeted therapies for rare and complex autoimmune diseases.
๐ช๐บ The European Commission has officially approved AbbVie's therapy for active polyarticular juvenile idiopathic arthritis in DMARD-IR patients aged two and older.
๐ถ This regulatory milestone expands the drug's authorized patient population to include young children as young as two years old.
๐ The approval validates the efficacy and safety of AbbVie's novel treatment for a specific subset of pediatric rheumatology patients.
๐ This decision is expected to facilitate commercialization across multiple European jurisdictions, potentially driving future revenue growth.
๐ The regulatory win reinforces AbbVie's leadership in developing targeted therapies for rare and complex autoimmune diseases.
Bullish Signals
EC approval expands market access for new arthritis therapy.
Validates efficacy in critical pediatric DMARD-inadequate responders.
The European Commission's approval of the new therapy for active polyarticular juvenile idiopathic arthritis represents a significant regulatory milestone that expands market access.
This approval specifically targets DMARD-inadequate responders aged two and older, validating the drug's efficacy in a critical pediatric patient population.
The successful European clearance strengthens AbbVie's pipeline of approved biologics and small molecules, contributing to its long-term growth strategy in rare diseases.
AbbVie (NYSE: ABBV) has diversified its pipeline by acquiring a stake in ADARx Pharmaceuticals during the company's IPO, gaining exposure to RNA interference drug candidates for rare disease indications. Simultaneously, Health Canada granted marketing authorization for AbbVie's EPKINLY for adults with relapsed or refractory follicular lymphoma, expanding its oncology franchise into later-line hematology care.
These strategic moves align with AbbVie's central narrative of replacing revenue from aging blockbusters like Humira and Imbruvica through a combination of internal research and business development deals. The ADARx investment signals the company's continued willingness to utilize minority stakes to secure optionality in newer modalities, while the EPKINLY approval directly supports the thesis that oncology must help offset erosion from older drugs.
However, these developments do not resolve concerns regarding the concentration of AbbVie's portfolio within a small cluster of major therapies. Analysts have flagged risks related to patent cliffs and pricing pressure, noting that new drugs only matter when they plug into a clear long-term replacement cycle. The article suggests weighing these pipeline moves against four specific warning signs identified for the company.
Simply Wall St analysts maintain a fair value target of $279 for AbbVie, emphasizing that successful execution on its pipeline and business development is critical to sustaining growth. The analysis highlights that while these new initiatives feed into the broader push for specialized, patent-protected treatments, investors must monitor how effectively management can execute this strategy amidst market challenges.
โ Health Canada approved EPKINLY for relapsed or refractory follicular lymphoma.
๐ New approvals aim to replace revenue from declining Humira and Imbruvica.
๐ผ Business development deals serve as a second engine alongside internal R&D.
โ ๏ธ Analysts warn concentration risks from patent cliffs and pricing pressure on major therapies.
๐งฌ AbbVie acquired a stake in ADARx Pharmaceuticals during its IPO to gain exposure to RNA interference drug candidates for rare disease indications.
โ Health Canada granted marketing authorization for AbbVie's EPKINLY for adults with relapsed or refractory follicular lymphoma.
๐ The new approvals and investments align with the strategy of replacing revenue from declining products like Humira and Imbruvica.
๐ผ AbbVie is utilizing business development deals as a second engine alongside internal R&D to secure optionality in newer modalities.
โ ๏ธ Analysts warn that AbbVie remains concentrated in a small cluster of major therapies, posing risks from patent cliffs and pricing pressure.
๐ Simply Wall St analysts maintain a fair value target of $279 for AbbVie based on historical data and forecasts.
Bullish Signals
Health Canada approved EPKINLY for later-line hematology care.
Acquired ADARx stake showing commitment to RNA therapies.
AbbVie successfully secured Health Canada marketing authorization for EPKINLY, expanding its oncology franchise into later-line hematology care.
The company acquired a stake in ADARx Pharmaceuticals during the IPO, demonstrating continued commitment to business development and exposure to RNA interference therapies.
Risk Factors
AbbVie remains concentrated in a small cluster of major therapies, creating vulnerability to patent cliffs and pricing pressure.
The company faces the ongoing challenge of replacing revenue from aging blockbusters like Humira and Imbruvica through its pipeline.
AbbVie Inc. shares approached a record high on September 24, 2026, trading at USD 265.07 after the company reported strong second-quarter financial results. The quarterly earnings per share (EPS) beat analyst consensus estimates by USD 0.04, reaching USD 3.65 against an expected USD 3.61. This positive performance contributed to a year-over-year revenue increase of 10.2%, with total revenue climbing to USD 16.99 billion compared to the prior year.
MarketBeat data highlights that AbbVie is successfully navigating its transition from Humira-era revenue by leveraging newer growth products while maintaining robust quarterly earnings momentum. The stock currently trades just 1.60% below its 52-week high of USD 269.39, reflecting investor confidence in the company's valuation and recent operational execution. Analyst consensus remains Moderate Buy with an average price target of USD 276.64, suggesting potential upside from current levels.
Looking ahead to the third quarter, AbbVie has provided EPS guidance ranging between USD 3.840 and USD 3.880 for investors to track against upcoming results. The company's market capitalization stands at approximately USD 468 billion as of late September 2026. While analyst price targets vary, with HSBC raising its target to USD 315, the overall sentiment remains positive driven by solid financial beats and strategic product transitions.
๐ Stock traded at $265.07, just 1.60% below its 52-week high.
๐ฐ Q2 EPS beat estimates by $0.04 at $3.65 per share.
๐ Revenue grew 10.2% YoY to $16.99 billion, beating consensus.
๐ Successfully replacing Humira revenue while preserving earnings momentum.
๐ฏ Analysts see 4.36% upside with a $276.64 average price target.
๐ AbbVie stock reached USD 265.07 on September 24, 2026, trading just 1.60% below its 52-week high of USD 269.39.
๐ฐ The company reported Q2 2026 EPS of USD 3.65, beating the consensus estimate of USD 3.61 by USD 0.04.
๐ Revenue grew 10.2% year over year to reach USD 16.99 billion, exceeding the USD 16.80 billion consensus.
๐ AbbVie is successfully replacing Humira-era revenue with newer growth products while preserving earnings momentum.
๐ฏ Analysts maintain a Moderate Buy consensus with an average price target of USD 276.64, implying 4.36% upside.
๐ HSBC raised its price target from USD 300 to USD 315 and maintained a Buy rating on the stock.
๐ฎ AbbVie set Q3 2026 EPS guidance between USD 3.840 and USD 3.880 for future investor comparison.
๐ Daily trading volume was 3,429,067 shares with a session range of USD 263.09 to USD 267.41.
Bullish Signals
Stock at $265.07, just 1.60% below 52-week high of $269.39.
Bullish Signals
AbbVie stock reached USD 265.07 on September 24, 2026, trading just 1.60% below its 52-week high of USD 269.39.
The company reported Q2 2026 EPS of USD 3.65, beating the consensus estimate of USD 3.61 by USD 0.04.
Revenue grew 10.2% year over year to reach USD 16.99 billion, exceeding the USD 16.80 billion consensus.
Analysts maintain a Moderate Buy consensus with an average price target of USD 276.64, implying 4.36% upside from current levels.
HSBC raised its price target from USD 300 to USD 315 and maintained a Buy rating on the stock.
Zacks Investment Research compares Pfizer (PFE) and AbbVie (ABBV), concluding that AbbVie currently offers a more attractive opportunity based on fundamentals. The analysis highlights AbbVie's successful navigation of Humira's loss of exclusivity, with its newer immunology drugs Skyrizi and Rinvoq generating over $14.6 billion in sales in the first half of 2026 and expected to reach combined sales above $31 billion for the full year.
AbbVie is projected to deliver more than 20% growth in 2026, supported by strong momentum in immunology, neuroscience, oncology, and aesthetics. The company expects total revenues to rise around 10% in 2026, driven by share gains in growing markets for its core franchises. Conversely, Pfizer faces a significant patent cliff later this decade with key products like Eliquis and Xeljanz facing expirations, expected to hurt sales by approximately $1.1 billion in 2026.
While Pfizer's stock has risen 13.2% year-to-date, AbbVie has jumped 16.0%, trading at a forward P/E of 17.01 compared to Pfizer's 9.56. Analyst consensus estimates for AbbVie imply a 40.5% increase in 2026 earnings, whereas Pfizer's estimates suggest a slight decrease. Despite both stocks holding a Zacks Rank #3 (Hold), the article favors AbbVie due to its visible growth profile and ability to offset blockbuster declines with new product launches.
๐ AbbVie expects combined Skyrizi and Rinvoq sales over $31B in 2026.
๐ Stock jumped 16% YTD with forward P/E of 17.01.
โ ๏ธ Faces Humira biosimilar erosion and soft Aesthetics unit sales.
๐ฐ Offers 1.9% dividend yield versus Pfizer's higher 6.1%.
๐ฌ Bolstering pipeline via Apogee Therapeutics acquisition for immunology assets.
๐ AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion in 2026, representing over 20% growth for the year.
๐ Pfizer faces a significant patent cliff later this decade with key products like Eliquis and Xeljanz facing expirations expected to hurt sales by approximately $1.1 billion in 2026.
๐ AbbVie's stock has jumped 16.0% year-to-date, outperforming Pfizer's 13.2% gain and trading at a forward P/E of 17.01 versus Pfizer's 9.56.
๐ฌ Pfizer plans an extensive phase III program for berobenatide, targeting the first potential approval in 2028 to drive growth in obesity and related comorbidities.
๐ Zacks consensus estimates for AbbVie imply a 40.5% increase in 2026 earnings, while Pfizer's estimates suggest a slight decrease of 7.5%.
๐ฅ AbbVie is bolstering its pipeline with the recent acquisition of Apogee Therapeutics to strengthen late-stage immunology assets.
โ ๏ธ AbbVie faces near-term headwinds including Humira biosimilar erosion and soft sales in its Aesthetics unit due to macroeconomic challenges.
๐ Pfizer expects high single-digit revenue CAGR starting from year-end 2028 as it recovers from the decline of COVID-related products.
๐ฐ AbbVie offers a dividend yield of 1.9%, while Pfizer provides a significantly higher yield of 6.1%.
Bullish Signals
Skyrizi/Rinvoq sales projected to exceed $31B in 2026.
Total revenue expected to rise ~10% in 2026.
Stock jumped 16.0% YTD, outperforming industry and Pfizer.
Robust pipeline with key data readouts and approvals coming.
Successfully replaced Humira with two successful immunology drugs.
Risk Factors
J&J's Icotyde launch increases competition for Skyrizi.
Competitive pressure may impact Skyrizi prescription trends.
Bullish Signals
AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion in 2026, with the drugs generating $14.6 billion in sales in the first half alone.
The company expects total revenues to rise around 10% in 2026, backed mainly by significant momentum in immunology and neuroscience products delivering share gains.
AbbVie's stock has jumped 16.0% year-to-date, outperforming the industry return of 12.7% and Pfizer's 13.2% gain.
The company boasts a robust pipeline with important data readouts, regulatory submissions, and approvals expected over the next couple of years.
AbbVie has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines that are performing extremely well.
Risk Factors
The launch of J&J's new oral pill Icotyde has increased competitive pressure for Skyrizi, which can impact the product's prescription trends.
AbbVie Inc. closed its shares at USD 265.21 on the NYSE on September 22, 2026, marking a modest 0.3 percent gain. The company reported strong second-quarter financial results with revenue rising 10.2 percent year over year to USD 16.99 billion and earnings per share (EPS) reaching USD 3.65, which beat analyst consensus estimates of USD 3.61 for EPS and USD 16.80 billion for revenue.
A significant regulatory milestone occurred when the European Commission approved RINVOQ for pediatric arthritis, adding a new indication to AbbVie's immunology portfolio. This approval is viewed as a concrete commercial step toward diversifying growth beyond its evolving portfolio, although the immediate market reaction was limited to a small daily price increase despite the stock trading near its yearly high.
Looking ahead, AbbVie provided adjusted EPS guidance for the third quarter of 2026 ranging between USD 3.84 and USD 3.88. Analysts maintain a Moderate Buy rating with an average price target of USD 276.64, suggesting potential upside from the current closing price. The company's market capitalization stands at approximately USD 469.10 billion as of September 22, 2026.
๐ ABBV stock closed up 0.3% at $265.21 with $469.1B market cap.
๐ฐ Q2 revenue surged 10.2% YoY to $16.99B, beating estimates.
๐ EPS reached $3.65, surpassing analyst expectations of $3.61.
โ European Commission approved RINVOQ for pediatric arthritis use.
๐ฎ Q3 adjusted EPS guidance set between $3.84 and $3.88.
๐ AbbVie stock closed at USD 265.21 on the NYSE, up 0.3 percent, with a market cap of approximately USD 469.10 billion.
๐ฐ Q2 2026 revenue surged 10.2 percent year over year to USD 16.99 billion, significantly beating consensus estimates.
๐ EPS for the quarter reached USD 3.65, surpassing analyst expectations of USD 3.61 and showing strong growth from the prior year.
โ The European Commission granted approval for RINVOQ in pediatric arthritis, expanding the drug's commercial potential.
๐ฎ AbbVie issued Q3 2026 adjusted EPS guidance between USD 3.84 and USD 3.88, providing clear forward-looking targets.
๐ The stock traded near its 52-week high of USD 267.47 but remained slightly below the peak at close.
๐ฏ Analysts maintain a Moderate Buy rating with an average price target of USD 276.64, indicating potential upside.
Bullish Signals
Q2 revenue hit $16.99B, up 10.2% YoY.
EPS beat estimates at $3.65 vs $3.61.
Got EC approval for RINVOQ in pediatric arthritis.
Guided to Q3 2026 EPS of $3.84-$3.88.
Bullish Signals
AbbVie reported Q2 revenue of USD 16.99 billion, representing a robust 10.2 percent year-over-year increase that significantly exceeded analyst consensus.
The company beat EPS estimates with results of USD 3.65 versus the expected USD 3.61, demonstrating strong operational performance.
AbbVie received European Commission approval for RINVOQ in pediatric arthritis, adding a valuable new indication to its immunology portfolio.
The company provided clear Q3 2026 adjusted EPS guidance ranging from USD 3.84 to USD 3.88, signaling confidence in near-term earnings.
AbbVie Inc. shares opened at $265.06 on September 22, 2026, near its 52-week high of $267.47, following a significant regulatory win for its key growth product RINVOQ. The European Commission approved the drug for use in children with active polyarticular juvenile idiopathic arthritis, expanding the treatment setting for this biologic agent.
Financially, AbbVie reported strong performance for the quarter ended June 30, 2026, with revenue rising 10.2% year-over-year to $16.99 billion. The company delivered an earnings per share (EPS) of $3.65, beating analyst consensus estimates by $0.04 and topping revenue expectations by $0.19 billion.
Despite the positive quarterly results and new drug approval, coverage noted that the full-year EPS outlook was a slight miss against expectations. With a market capitalization of approximately $468.31 billion, the stock trades at a valuation where earnings disappointments are closely scrutinized by investors.
๐ AbbVie stock opened near 52-week high after pediatric RINVOQ approval.
๐ New pediatric arthritis indication adds growth segment for RINVOQ.
๐ Q2 revenue hit $16.99 billion, up 10.2% year-over-year.
๐ฐ Q2 EPS of $3.65 beat estimates by $0.04.
โ ๏ธ Full-year EPS outlook slightly misses current market expectations.
๐ AbbVie stock opened near its 52-week high of $267.47 following European Commission approval for RINVOQ in pediatric patients.
๐ The regulatory decision extends RINVOQ's use to children with active polyarticular juvenile idiopathic arthritis, adding a new growth segment.
๐ Q2 revenue reached $16.99 billion, representing a 10.2% increase from the prior-year period.
๐ฐ The company reported EPS of $3.65 for the quarter ended June 30, 2026, beating consensus estimates by $0.04.
๐ฏ Revenue exceeded analyst expectations by $0.19 billion during the second quarter of fiscal year 2026.
โ ๏ธ Analysts described the full-year EPS outlook as a slight miss against current market expectations.
Bullish Signals
European Commission approved RINVOQ for children's arthritis.
Q2 revenue grew 10.2% YoY to $16.99B.
Beat EPS consensus by $0.04 at $3.65.
Risk Factors
Full-year EPS outlook missed expectations.
Stock near 52-week high limits upside.
Bullish Signals
AbbVie received European Commission approval for RINVOQ in children with active polyarticular juvenile idiopathic arthritis, expanding its key growth product portfolio.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)